High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the
liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.